Skip to main content

Day: March 16, 2026

Tilray Brands Enters Agreement to Acquire BrewDog’s Key U.S. Assets, Expanding Its U.S. Craft Beer Platform

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis, and wellness industries, today announced that the Company has entered into an asset purchase agreement to acquire certain strategic assets of BrewDog in the United States, including its brewery, pub, and hotel in Columbus, Ohio, as well as the pubs in New Albany, Ohio, Cleveland, Ohio, and Las Vegas, Nevada. As one of the largest craft beer brands in Ohio, this acquisition aligns with Tilray’s regional jewel strategy. Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands, said, “The acquisition of BrewDog’s key U.S. assets strengthens our U.S. beverage platform and advances our...

Continue reading

Nuclear Vision Acquires Manganese Carbonate Projects in Slovakia’s “Battery Belt”

VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) — Nuclear Vision Limited (“Nuclear Vision” or the “Company”)(CSE: NUKV) is pleased to announce that, further to its news release of January 21, 2026, it has paid an aggregate of €100,000 and issued an aggregate of 10,000,000 common shares of the Company (each, a “Share”) at a deemed price of $0.24 per Share pursuant to the assignment of option agreement and consent to assignment dated January 21, 2026 (the ”Assignment Agreement”) with Private Equity Pty and Kluane Capital FZCO (together, the “Assignor”), both of which are arm’s length parties to the Company, whereby the Assignor assigned to the Company all of its rights, title and interest in an existing option to purchase agreement dated January 14, 2026 (the “Option Agreement”) with VMS Exploration S.R.O. (“VMS”) (the ”Acquisition”)....

Continue reading

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer’s novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancer Continued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026 Generated $218.5 million in gross proceeds from a follow-on public offering, further strengthening the Company’s balance sheet; ended 2025 with $505.4 million in cash, cash equivalents,...

Continue reading

Weight Watchers Announces Fourth Quarter and Full Year 2025 Results

2025 Total Revenue and Adjusted EBITDA1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026  Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA1 of $18 million and Adjusted EBITDA Margin1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the fourth quarter and full year...

Continue reading

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

– Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results – – Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 – – New, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) progressing toward clinical development – – Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 – – Oral, IL-17AA/AF inhibitor (ZB021) Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end – – Up to $250 million non-dilutive, multi-tranche debt financing secured from Pharmakon...

Continue reading

Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the First Quarter of 2026

CHICAGO, March 16, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), a commercial mortgage real estate investment trust, announced that its board of directors has declared a regular quarterly cash dividend of $0.47 per share for the first quarter of 2026. The regular quarterly dividend, which equates to an annualized rate of $1.88 per common share, is payable on April 15, 2026, to shareholders of record as of the close of business on March 31, 2026. About Chicago Atlantic Real Estate Finance, Inc. Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) is a market-leading commercial mortgage REIT utilizing significant real estate, credit and cannabis expertise to originate senior secured loans primarily to state-licensed cannabis operators in limited-license states in the United States. REFI is...

Continue reading

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) — Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer (“OEM”) distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices (“IBT”), a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT’s established sales channels, expanding market access and supporting Dyadic’s objective of generating ongoing, product-based revenues. The initial products expected...

Continue reading

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY (a public company incorporated with limited liability in Ireland) WISDOMTREE WTI CRUDE OIL 3X DAILY SHORT SECURITIES ISIN: XS2819844387

16 March 2026 LEI: 2138003QW2ZAYZODBU23 LSE Code: 3OIS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland) WISDOMTREE WTI CRUDE OIL 3X DAILY SHORT SECURITIES ISIN: XS2819844387 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES MEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser. NOTICE is hereby given that, pursuant to the provisions of the trust deed dated 30 November 2012 (as amended) constituting (inter alia) the WisdomTree WTI Crude Oil 3x Daily Short Securities (the “Affected Securities”) and made between (1) WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”),...

Continue reading

Real Messenger Announces Receipt of Nasdaq Notification Letter Regarding Minimum Price Deficiency

Costa Mesa, CA, March 16, 2026 (GLOBE NEWSWIRE) — Real Messenger Corporation (“Real Messenger” or the “Company”) (Nasdaq: RMSG), an innovative chat-based platform reimagining real estate connections, today announced that it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2026, notifying the Company that it is not in compliance with the requirement to maintain a minimum closing bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s class A ordinary shares was below $1 per share for the last 30 consecutive business days (i.e. from January 29, 2026 to March 12, 2026). The Nasdaq Letter is only a notification of deficiency. It does not result in the immediate delisting and has no current effect on the listing or trading of the...

Continue reading

Aurora Spine Corporation to Participate in the 38th Annual ROTH Conference

CARLSBAD, Calif., March 16, 2026 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced it will participate in the 38th Annual ROTH Conference on March 22-24, hosted by Roth Capital Partners. The conference will be held March 22-24, 2026 at the Ritz-Carlton in Laguna Niguel, California and the management team will be available for one-on-one meetings with investors at the conference. Investors attending the conference who are interested in scheduling a meeting with management, can do so by contacting their Roth representative, or by emailing asapf@lythampartners.com. About the Roth Capital Partners Conference The Annual ROTH Conference is one of the largest in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.